- Research article
- Open Access
- Open Peer Review
Computer-assisted assessment of the Human Epidermal Growth Factor Receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls
© Hall et al; licensee BioMed Central Ltd. 2008
- Received: 18 January 2008
- Accepted: 05 June 2008
- Published: 05 June 2008
Breast cancers that overexpress the human epidermal growth factor receptor 2 (HER2) are eligible for effective biologically targeted therapies, such as trastuzumab. However, accurately determining HER2 overexpression, especially in immunohistochemically equivocal cases, remains a challenge. Manual analysis of HER2 expression is dependent on the assessment of membrane staining as well as comparisons with positive controls. In spite of the strides that have been made to standardize the assessment process, intra- and inter-observer discrepancies in scoring is not uncommon. In this manuscript we describe a pathologist assisted, computer-based continuous scoring approach for increasing the precision and reproducibility of assessing imaged breast tissue specimens.
Computer-assisted analysis on HER2 IHC is compared with manual scoring and fluorescence in situ hybridization results on a test set of 99 digitally imaged breast cancer cases enriched with equivocally scored (2+) cases. Image features are generated based on the staining profile of the positive control tissue and pixels delineated by a newly developed Membrane Isolation Algorithm. Evaluation of results was performed using Receiver Operator Characteristic (ROC) analysis.
A computer-aided diagnostic approach has been developed using a membrane isolation algorithm and quantitative use of positive immunostaining controls. By incorporating internal positive controls into feature analysis a greater Area Under the Curve (AUC) in ROC analysis was achieved than feature analysis without positive controls. Evaluation of HER2 immunostaining that utilized membrane pixels, controls, and percent area stained showed significantly greater AUC than manual scoring, and significantly less false positive rate when used to evaluate immunohistochemically equivocal cases.
It has been shown that by incorporating both a membrane isolation algorithm and analysis of known positive controls a computer-assisted diagnostic algorithm was developed that can reproducibly score HER2 status in IHC stained clinical breast cancer specimens. For equivocal scoring cases, this approach performed better than standard manual evaluation as assessed by ROC analysis in our test samples. Finally, there exists potential for utilizing image-analysis techniques for improving HER2 scoring at the immunohistochemically equivocal range.
- Receiver Operator Characteristic Curve
- Optimal Receiver Operator Characteristic Curve
The human epidermal growth factor receptor 2 (HER2) gene on chromosome 17 is amplified in 20% to 30% of breast cancer patients . The protein product is a transmembrane receptor tyrosine kinase whose overexpression in breast cancers is predominantly due to HER2 gene amplification . The proper evaluation of HER2 status is crucial to patient care as its overexpression and/or amplification is associated with less favorable clinical outcomes and relatively poor response to certain treatments [3, 4]. Moreover, with the development of effective targeted therapies such as Trastuzumab (Herceptin), a monoclonal antibody to HER2, which are effective only in tumors with HER2 overexpression, the clinical ramifications of accurately assessing HER2 status is further underscored. Thus, accurate HER2 assessment is vital to the identification of breast cancer patients who would benefit from anti-HER2 therapy.
Given the clinical impact of HER2 overexpression, there has recently been a heightened emphasis on reliably assessing HER2 status in breast cancers [5–9]. Guidelines have been issued jointly by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) in order to establish protocols for evaluating HER2 status that involve both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) [6, 10]. Recently a new standard for assessing HER2 expression was instituted that requires that both IHC and FISH be conducted when scores from either fall into the newly established equivocal ranges. ASCO/CAP recommended that an IHC score of 2+ or a FISH score (ratio of HER2/CEP17 genes) of 1.8–2.2 be considered equivocal and that the specimen be graded with the complementary modality, or repeated in the case of FISH. (An alternate option is to reassess the immunohistochemistry at a reference laboratory.)
In light of the pressing need for accurate determination of HER2 overexpression, the authors of the above ASCO/CAP study have acknowledged the use of image analysis as a viable approach for assessment. Previous work with image analysis systems have focused on the validation of commercially available technology in the clinic by demonstrating greater accuracy in quantification of HER2 immunohistochemistry when compared to manual interpretation [4, 11–13], and reduction in inter-observer variability with systems such as ACIS (automated cellular imaging system) . However, due to the proprietary nature of such systems, the technical processes that lead up to a HER2 score are often not transparent to the pathologist. This may lead to interpretation difficulties as the exact tissue features being quantified and the methods used to perform the HER2 assessment have not been made available for peer review. For instance, the pathologist has little information regarding how well and to what extent the image analysis software is able to quantify membrane staining. Furthermore, the pathologist does not have access to the manufacturer's criteria or data that established the universal "cutoff score" for HER2 positivity . This can be problematic as cutoff values are not necessarily applicable across laboratories due to variations in staining characteristics which can arise as a result of different choices in antibodies, laboratory equipment, and fixation procedures . Veiling the relevant technical information that is used to render clinical decisions is somewhat inconsistent with the current environment of evidence-based medicine. In the face of these pressing concerns, to our knowledge, only one commercial system has revealed some basic outlines of the image processing methods behind their commercially based system .
Furthermore, the cost of performing the analysis may actually serve as a barrier to mainstream adoption of this technology in practice. Skaland et. al. has contributed valiantly in this realm by using readily available (and free) NIH image processing software to analyze images of HER2 stained breast cancer specimens . However, these algorithms use generic image processing methods not designed specifically for these images. For instance, no morphologically based operators are used to detect stained membrane pixels, but rather a simple intensity threshold is used. Therefore, only darkly stained images could be analyzed in their experiments. As a result, we have tried to introduce algorithms specifically tailored to this application.
In this manuscript, we describe the design, development and evaluation of a new suite of algorithms to assist in increasing the precision (i.e. number of scoring levels) at which HER2 immunostains are quantified. We provide a detailed description of the workflow and associated processes that are used to evaluate HER2 stained breast slides and compute the HER2 expression score. We describe three clinically based image features used in our system and compare their performance with manual scoring techniques in assessing specimens. The performance results of the computer-assisted quantification algorithms based on the newly developed image features are then compared with manual scoring using Receiver Operator Characteristic (ROC) analysis. In addition, the adequacy of the quantification algorithm is crucially examined in the equivocal scoring ranges in order to demonstrate its applicability in the laboratory. Finally, we discuss the capacity of the system to be optimally calibrated for the specific conditions of the given laboratory. By increasing the precision with which HER2 immunohistochemistry is quantified, we anticipate that breast cancer patients who might benefit from anti-HER2 therapy will be accurately identified, while the remaining subpopulation of patients will be spared a costly and potentially harmful treatment.
Designing the Computer-Assisted Quantification Scheme
Translating Manual HER2 Assessment into Computer-Related Tasks
A. Visually examines tissue
I. Captures digital image of relevant area of tissue
B. Locates invasive carcinoma
C. Examines intensity of stain at cytoplasmic membrane
II. Identifies stained membrane areas (pixels) and quantifies intensity on 0–255 scale
D. Examines completeness of membrane staining
III. Quantifies percentage of membrane staining per cell
E. Examines percent positive cells
IV. Counts positive cancer cells and divides by total number of cancer cells
F. Compares with positive tissue controls
V: Takes digital image of control, quantifies control, and uses it to normalize patient HER2 score.
Overview of Computer-Assisted Quantification Scheme
Case selection, processing, and manual grading
The specimens used in these studies consisted of 99 breast cancer cases that had been diagnosed between January 2005 and March 2007 and stored in archives at the Department of Pathology and Laboratory Medicine at Robert Wood Johnson University Hospital, New Brunswick, and N.J. During this period of time it was standard procedure for both assays to be performed. Cases which had received an IHC score of 0 or 1+ were limited in order to enrich the amount of 2+ cases (considered equivocal) to approximately 25% of the data. The purpose of this experimental design was that since 2+ cases are considered equivocal, they represent the patient population that would tend to benefit most from the use of computer aided quantification. Specimens with significant mechanical crushing and sectioning artifacts were omitted from the study to arrive at the final 99 cases. Both invasive ductal and lobular carcinomas were included in the experiments.
Immunohistochemical staining was performed at the Department of Pathology and Laboratory Medicine at Robert Wood Johnson University Hospital utilizing an automated immunostainer, Ventana BenchMark IHC/ISH system (Ventana Medical Systems, Inc. Tucson, AZ). Ventana PATHWAY HER-2 (clone CB-11) was used for the primary detection of c-erbB-2 antigen in sections of formalin fixed, paraffin embedded tissue. A known 3+, FISH positive control was fixed on each slide along with the patient sample in order to analyze both under identical staining conditions.
Manual immunohistochemical grading was performed by a board certified surgical pathologist (P.J.) at Robert Wood Johnson University Hospital according tithe Scoring Guide for the Interpretation of Ventana Pathway HER2 Staining of Breast Carcinomas . Briefly, if no membrane staining was observed the specimen was scored as 0. Faint, partial staining of the membrane was scored as 1+. Weak complete staining of the membrane, >10% of cancer cells was scored as 2+. Intense complete staining of the membrane, >10% of cancer cells, was scored as 3+. A score of 2+ or greater is considered positive according to the manufacturer's instructions.
Specimens were sent to Genzyme Genetics (Westborough, MA) for FISH analysis and the ratio of discrete signals for the HER2 gene and centromere probe for chromosome 17 (CEP17) was reported. A ratio of HER2 gene/CEP17 ≥ 2.3 was considered positive for HER2 overexpression.
Image Selection and Capturing
A board certified pathologist (P.J.) delineated the region of invasive carcinoma, and then a resident pathologist (M.I.) used a robotic microscope to digitally acquire images at 20× magnification within the specified boundaries. The control from each slide was also digitized at 20× magnification. All images are taken with an Olympus AX70 microscope (Olympus America Inc., Melville, NY) equipped with a Prior six-way robotic stage and motorized turret (Prior Scientific, Inc., Rockland, MA) and Olympus DC330 720-line 3-Chip video camera at 1360 × 1024 pixel resolution and a fixed exposure time of 1/600 s. This allows the digital images to be captured through red, green, and blue channels, and thus, span the entire visible range.
Membrane Isolation Algorithm (MIA)
Image Features and HER2 Score
where I is the set of intensities derived from the pixels retained from performing the MIA on p the patient tissue; the bar denotes the mean function.
M c is defined similarly to M p except that the calculation is based on c the control tissue .
where N is the total amount of pixels in the image, d is the number of DAB stained pixels after pre-processing. The coefficient d/N is used as an approximation for the percentage of stained cells. Results were also gathered for median-based features; however, results were similar, and therefore not included in this manuscript.
Hardware and Implementation
An Intel Core 2 Duo T7400 (2.16 GHz) computer with 1.0 GB memory was used for processing each image. The color decomposition algorithm was implemented in Java. All other processing was implemented utilizing Matlab (The MathWorks, Inc. Natwick, MA) code. The color decomposition and membrane isolation together took approximately 10–20 seconds per image to complete.
Receiver Operator Characteristic curve analysis was used to compare the accuracy of the manual and automated computerized methods for grading IHC. FISH assays were used as an independent means for assessing IHC scores. The area -under- the -curve (AUC) was calculated for each ROC curve utilizing the trapezoidal rule  in order to compare the accuracy of each method as a test for FISH positivity. Since the data are derived from the same patient cases, p-values are calculated using a nonparametric method based on the Mann-Whitney-U Statistic . The McNemar Test for correlated proportions [23, 24]was used to calculate the p-values for differences between sensitivity or specificity.
Institutional Review Board Approval
Institutional Review Board approval was obtained for this retrospective study through protocol (IRB #5381).
Summary of HER2 manual grading and FISH scores
IHC = 0
IHC = 1
IHC = 2
IHC = 3
1.8 – 2.2
Analysis of Specimens using Stained Membrane Regions with and without controls
Analysis of Specimens using Stained Membrane Regions incorporating Both Controls and Percent Stained Area
The results from Figure 7 indicated that the performance of the system based on M n score was similar to that of manual scoring. Consequently, the percent stained area was incorporated into the M a feature through an addition of the d/N coefficient. The M a ROC curve (red line) is compared to the ROC curve generated from manual scoring (black line, Fig. 7). As evident in this plot, the AUC from the M a feature is significantly greater than that derived from manual scoring (p < .05). More importantly, the difference between the two scoring systems is most pronounced at the clinically crucial point: the equivalent score of 2+. The arrow (Fig. 7) denotes an example M a cutoff point that has a statistically lower false positive rate than that derived by using the 2+ cutoff score.
Quantification of Equivocal Cases
To estimate a robust classification performance of the system on only these 2+ cases, an iterative leave-one-out classification experiment was performed. The cutoff point to determine FISH positivity was based on twenty-one training samples. This cutoff point was chosen as the maximum cutoff point yielding 100% sensitivity (i.e. fix sensitivity at 100% while maximizing specificity). Then the novel case not used in training was scored based on the cut-off score. Correct was defined as either above the cut-off and FISH ≥2.3 (a true positive decision), or below the cut-off score and FISH <2.3 (a true negative). Repeating the experiment 1000× with a randomly chosen test case, we arrived at an estimate of the system's classification performance on 2+ cases. From this experiment, the 2+ test case was correctly classified 64% of the time, whereas manual scoring was only able to correctly classify 23% of the cases (5/22: 5 of the 22 2+ cases, which are considered positive, were also FISH positive). There was a reduction false positive rate (percentage of FISH negative cases considered FISH positive) from 100% to 31%, as 100% of manually scored 2+ cases are considered by Ventana scoring guidelines to be positive. Lastly, the false negative rate was only 4%.
In this retrospective study of 99 cases of breast carcinoma, we have demonstrated the processes and methods behind the design, development, and evaluation of an image-based, computer-assisted HER2 immunohistochemistry quantification scheme. The result was an introduction of a membrane isolation algorithm and the quantitative use of positive staining controls. The membrane isolation algorithm in combination with the quantitative use of controls (M n feature) was shown to be superior to analyzing the patient tissue alone (M p feature). This improvement is hypothesized to stem from the unique staining conditions of each slide that is reflected in both the patient and control sample. Furthermore, this clinically based combination (M n ) demonstrated an ability to correlate with gene amplification results that was similar to that of manual assessment.
With the establishment of new guidelines defining the equivocal IHC scoring range of 2+, it was hypothesized that computer-assisted image analysis may be useful in assisting in the manual interpretation of these cases. As a result, we explored the addition of an area coefficient to the M n feature to form the M a feature. Using this feature, significant reduction in false positive rate was evidenced especially in the 2+ intensity region (Fig. 7), along with an overall greater AUC than manual grading. A greater AUC is interpreted as a greater probability that a randomly selected FISH positive case would have a higher score than a randomly chosen FISH negative case. In addition, because the computer can distinguish varying levels of intensity and area within this 2+ category, we chose a specific point on the ROC curve derived solely from 2+ cases that yielded 100% sensitivity of FISH positive cases, while minimizing the amount of false positive cases (Fig. 8). This produced a cutoff point at a clinically desirable sensitivity and specificity that was selected according to our institutional staining variations. Leave-one-out cross validation experiments based on this cutoff showed promising improvement for equivocal cases when compared to manual scoring. As all 2+ cases are considered positive by Ventana scoring methods, usage of the M a feature to analyze HER2 immunohistochemistry shows the possibility of false positive rate reduction, which would lead to the reduction of patients exposed to unnecessary treatment toxicity. One advantage of our approach to measuring HER2 staining is that unlike clinical scoring, which has the ability of differentiating only 4 scoring levels, computer-assisted quantification outputs a nearly continuous variable, for which fine tuned cut-offs can be identified.
Previously published systems differ in many respects from our proposed algorithms. Firstly, many commercially available systems have a universal cutoff score for HER2 overexpression that is not optimized for a given laboratory, in spite of well established variations in intra-laboratory conditions . However, statistical analyses based on the data collected from that particular institution can provide a meaningful and institutional-specific, cutoff value for immunostains such as HER2 . ROC analysis illustrates the benefits of adjusting for such variations leading to improved sensitivity and specificity. With this information, the selection of a particular cutoff score can be chosen according to each institution's operating parameters, enabling pathologists to estimate the likelihood that a certain score is correct based on the sensitivity and specificity of the chosen cutoff point. In addition, both commercial and noncommercial systems  have thus far neglected to include the quantitative analysis of positive HER2 controls in their calculation of a HER2 score. As evidenced in our study, there is sometimes marked variation in staining intensity which is often accounted for in manual scoring techniques, but neglected in published computer-assisted methods. Consequently, our algorithms specifically take into account this variation in staining. And lastly, our algorithms are morphologically based (unlike ), demonstrate improvement in scoring 2+ cases, and freely available (unlike many proprietary commercial systems) to further research and improvement.
In the future, research efforts may be concentrated in defining image features that better reflect percent of cancer cells stained (Table 1, Step E) or completeness of membrane staining (Table 1, step D), and providing segmentation algorithms that delineate the invasive component of the carcinoma (Table 1, step B). Indeed, the development of the image-based algorithms required to fully assess HER2 immunohistochemistry is only in its nascent stages, and what we have demonstrated here is only a first step towards that goal. It is hoped that with the combination of features that accurately quantify HER2 expression and the ability to distinguish not just 4 classes of HER2 immunostaining, but rather a continuum, the correlation between HER2 overexpression and response to trastuzumab therapy can be enhanced.
This work has demonstrated the promise of developing clinically based algorithms to assist in the quantification of the HER2 immunostain. A membrane isolation algorithm was developed that can be readily applied to quantification of membrane stained images. In addition, quantitative use of positive staining controls was shown to significantly increase the diagnostic ability of the features used to quantify HER2 membrane staining. The M n feature used showed similar ability to predict FISH positivity when compared to manual scoring. Furthermore, potential improvement in specificity for the 2+ specimens was demonstrated using the Ma feature. Lastly, by using ROC analysis, we indicated a process by which an institution can derive a cutoff score for computer-assisted image analysis systems that can account for their unique laboratory staining conditions. In the future, we hope to validate this method by analyzing a larger series of independent samples for which both IHC and FISH scores of HER2 are available.
Indeed, we have shown that computer-assisted image-analysis can enhance the degrees to which quantification of immunohistochemistry can be achieved, and improve the correlation of IHC with genetic amplification. Ultimately, much investigation remains to be done in accurately determining which patients not only overexpress HER2, but also, which, in the end, will respond to therapy.
This research was funded, in part, by a grant from the NIH through contract 5R01EB003587-02 from the National Institute of Biomedical Imaging and Bioengineering. Additional Funds were provided by The Cancer Institute of New Jersey and the Department of Defense via contract # W81XWH-06-1-0514.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235 (4785): 177-182. 10.1126/science.3798106.View ArticlePubMedGoogle Scholar
- Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986, 232 (4758): 1644-1646. 10.1126/science.3012781.View ArticlePubMedGoogle Scholar
- Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998, 16 (6): 413-428.View ArticlePubMedGoogle Scholar
- Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, et al: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993, 53 (20): 4960-4970.PubMedGoogle Scholar
- Leong TY, Leong AS: Controversies in the assessment of HER-2: more questions than answers. Adv Anat Pathol. 2006, 13 (5): 263-269. 10.1097/01.pap.0000213043.16200.92.View ArticlePubMedGoogle Scholar
- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2007, 131 (1): 18-PubMedGoogle Scholar
- Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000, 18 (21): 3651-3664.PubMedGoogle Scholar
- Bankfalvi A, Boecker W, Reiner A: Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests. Int J Oncol. 2004, 25 (4): 929-935.PubMedGoogle Scholar
- Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002, 20 (14): 3095-3105.PubMedGoogle Scholar
- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25 (1): 118-145. 10.1200/JCO.2006.09.2775.View ArticlePubMedGoogle Scholar
- Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH, Hynan L, Ashfaq R: Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001, 116 (4): 495-503. 10.1309/TMUW-G4WB-LXJ2-FUDN.View ArticlePubMedGoogle Scholar
- Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ: Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006, 48 (3): 258-267. 10.1111/j.1365-2559.2005.02322.x.View ArticlePubMedGoogle Scholar
- Bloom K, Harrington D: Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004, 121 (5): 620-630. 10.1309/Y73U-8X72-B68T-MGH5.View ArticlePubMedGoogle Scholar
- Leong AS: Quantitation in immunohistology: fact or fiction? A discussion of variables that influence results. Appl Immunohistochem Mol Morphol. 2004, 12 (1): 1-7.View ArticlePubMedGoogle Scholar
- Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, Gholap GA, Gholap AS, Barsky SH: Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A. 2007, 71 (5): 273-285.View ArticlePubMedGoogle Scholar
- Skaland I, Ovestad I, Janssen EAM, Klos J, Kjellevold KH, Helliesen T, Baak JP: Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. Journal of Clinical Pathology. 2008, 61: 68-71. 10.1136/jcp.2007.046763.View ArticlePubMedGoogle Scholar
- Seidal T, Balaton AJ, Battifora H: Interpretation and quantification of immunostains. Am J Surg Pathol. 2001, 25 (9): 1204-1207. 10.1097/00000478-200109000-00013.View ArticlePubMedGoogle Scholar
- Chen W RM, Foran DJ.: A prototype for unsupervised analysis of tissue microarrays for cancer research and diagnostics. IEEE Transactions on Information Technology in Biomedicine. 2004, 8 (2): 89-96. 10.1109/TITB.2004.828891.View ArticlePubMedGoogle Scholar
- Ventana Scoring Guide. [http://www.ventanamed.com/products/files/ScoringGuide.pdf]
- Otsu N: A threshold selection method from gray-level histograms. IEEE Trans Sys, Man, Cyber. 1979, 9 (1): 62-66.View ArticleGoogle Scholar
- Varma M, Zisserman A: A statistical approach to texture classification from single images. INT J COMPUT VISION. 2005, 62 (1-2): 61-81. 10.1007/s11263-005-4635-4.View ArticleGoogle Scholar
- DeLong ER DDM, Clarke-Pearson DL: Comparing the Area Under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.View ArticlePubMedGoogle Scholar
- VassarStats: Web Site for Statistical Computation. [http://faculty.vassar.edu/lowry/VassarStats.html]
- McNemar Q: Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947, 12: 153-157. 10.1007/BF02295996.View ArticlePubMedGoogle Scholar
- Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001, 19 (10): 2587-2595.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2342/8/11/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.